RU94045908A - COMPOSITION, METHOD FOR PROCESSING A NEOPLASTIC CELL, METHOD FOR DESTROYING A NEOPLASTIC CELL - Google Patents

COMPOSITION, METHOD FOR PROCESSING A NEOPLASTIC CELL, METHOD FOR DESTROYING A NEOPLASTIC CELL

Info

Publication number
RU94045908A
RU94045908A RU94045908/14A RU94045908A RU94045908A RU 94045908 A RU94045908 A RU 94045908A RU 94045908/14 A RU94045908/14 A RU 94045908/14A RU 94045908 A RU94045908 A RU 94045908A RU 94045908 A RU94045908 A RU 94045908A
Authority
RU
Russia
Prior art keywords
composition according
cell
composition
protein
neoplastic
Prior art date
Application number
RU94045908/14A
Other languages
Russian (ru)
Other versions
RU2130780C1 (en
Inventor
Дж.Розенблюм Майкл
К.Шоувер Лаура
Original Assignee
Рисерч Дивелопмент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рисерч Дивелопмент Фаундейшн filed Critical Рисерч Дивелопмент Фаундейшн
Priority claimed from PCT/US1993/003292 external-priority patent/WO1993021232A1/en
Publication of RU94045908A publication Critical patent/RU94045908A/en
Application granted granted Critical
Publication of RU2130780C1 publication Critical patent/RU2130780C1/en

Links

Claims (27)

1. Композиция, отличающаяся тем, что содержит конъюгат белка, проявляющего специфичность связывания в отношении антигенного домена белка с-erb В-2 и происходящего из растения токсина, причем токсин выбран из группы, состоящей из гелонина, рекомбинантного гелонина полной длины, фрагментов гелонина и производных гелонина.1. The composition, characterized in that it contains a conjugate of a protein exhibiting binding specificity for the antigenic domain of the c-erb B-2 protein and the toxin derived from the plant, the toxin selected from the group consisting of gelonin, recombinant gelonin full length, gelonin fragments and gelonin derivatives. 2. Композиция по п. 1, отличающаяся тем, что она имеет специфичность связывания относительно внеклеточного эпитопа с-erb В-2. 2. The composition according to p. 1, characterized in that it has binding specificity relative to the extracellular epitope of c-erb B-2. 3. Композиция по п. 1, отличающаяся тем, что упомянутый выше белок содержит Vн-сегмент.3. The composition according to p. 1, characterized in that the aforementioned protein contains a V n -segment. 4. Композиция по п. 1, отличающаяся тем, что упомянутый выше белок содержит тяжелую цепь интактного иммуноглобулина. 4. The composition according to p. 1, characterized in that the aforementioned protein contains a heavy chain of intact immunoglobulin. 5. Композиция по п. 1, отличающаяся тем, что упомянутый выше белок содержит VL-сегмент.5. The composition according to p. 1, characterized in that the aforementioned protein contains a V L segment. 6. Композиция по п. 5, отличающаяся тем, что упомянутый выше белок содержит, кроме того, VH-сегмент.6. The composition according to p. 5, characterized in that the protein mentioned above contains, in addition, a V H segment. 7. Композиция по п. 1, отличающаяся тем, что упомянутый выше белок содержит легкую цепь интактного иммуноглобулина. 7. The composition according to p. 1, characterized in that the aforementioned protein contains an intact immunoglobulin light chain. 8. Композиция по п. 7, отличающаяся тем, что упомянутый выше белок содержит, кроме того, тяжелую цепь интактного иммуноглобулина. 8. The composition according to p. 7, characterized in that the aforementioned protein contains, in addition, a heavy chain of intact immunoglobulin. 9. Композиция по п. 1, отличающаяся тем, что упомянутый выше белок представляет собой одноцепочечное антитело. 9. The composition according to p. 1, characterized in that the aforementioned protein is a single chain antibody. 10. Композиция по п. 1, отличающаяся тем, что упомянутый выше белок представляет собой ТАb 250 или ВАСh-250. 10. The composition according to p. 1, characterized in that the aforementioned protein is a TAb 250 or BACh-250. 11. Композиция по п. 1, отличающаяся тем, что упомянутый выше токсин растительного происхождения имеет гораздо более слабое действие на клетки, если он не конъюгирован с упомянутой направляющей частью молекулы. 11. The composition according to p. 1, characterized in that the aforementioned toxin of plant origin has a much weaker effect on the cells, if it is not conjugated with the said guiding part of the molecule. 12. Композиция по п. 1, отличающаяся тем, что упомянутый токсин выбран из группы, состоящей из нативного токсина и рекомбинантного токсина. 12. The composition according to p. 1, characterized in that said toxin is selected from the group consisting of a native toxin and a recombinant toxin. 13. Композиция по п. 1, отличающаяся тем, что упомянутый выше конъюгат представляет собой слитый белок между направляющей частью и модулятором роста клеток. 13. The composition according to p. 1, characterized in that the aforementioned conjugate is a fusion protein between the guide part and the cell growth modulator. 14. Композиция по п.1, отличающаяся тем, что является фармацевтической. 14. The composition according to claim 1, characterized in that it is pharmaceutical. 15. Композиция по п. 1, отличающаяся тем, что она содержит, кроме того, фармацевтически приемлемый носитель. 15. The composition according to p. 1, characterized in that it contains, in addition, a pharmaceutically acceptable carrier. 16. Композиция по п.15, отличающаяся тем, что является разовой дозой. 16. The composition according to p. 15, characterized in that it is a single dose. 17. Способ обработки неопластической клетки, предусматривающий введение эффективной дозы композиции по п.1 к этой клетке. 17. A method for treating a neoplastic cell, comprising administering an effective dose of the composition of claim 1 to the cell. 18. Способ по п. 17, отличающийся тем, что упомянутая неопластическая клетка отличается избыточной экспрессией белка с-erb В-2. 18. The method according to p. 17, characterized in that said neoplastic cell is characterized by excessive expression of c-erb B-2 protein. 19. Способ по п. 17, отличающийся тем, что упомянутая клетка выбрана из группы, состоящей из клетки рака молочной железы, рака яичников, рака легких, рака слюнной железы, опухолевой клетки желудка, клетки аденокарциномы толстой кишки и клетки лейкоза костного мозга. 19. The method of claim 17, wherein said cell is selected from the group consisting of breast cancer cells, ovarian cancer, lung cancer, salivary gland cancer, gastric tumor cell, colon adenocarcinoma cell, and bone marrow leukemia cell. 20. Способ по п. 17, отличающийся тем, что упомянутая выше композиция замедляет скорость роста упомянутых клеток. 20. The method according to p. 17, characterized in that the above composition slows down the growth rate of said cells. 21. Способ обработки по п. 17, отличающийся тем, что упомянутая неопластическая клетка является клеткой человека или животного. 21. The processing method according to p. 17, characterized in that the said neoplastic cell is a human or animal cell. 22. Способ по п. 21, отличающийся тем, что упомянутая композиция предотвращает рецидив неопластического состояния. 22. The method according to p. 21, characterized in that the said composition prevents the relapse of the neoplastic state. 23. Способ по п. 21, отличающийся тем, что упомянутая композиция продлевает время жизни хозяина неопластической клетки. 23. The method according to p. 21, characterized in that the said composition extends the life time of the owner of the neoplastic cell. 24. Способ по п. 17, отличающийся тем, что неопластическую клетку обрабатывают in vitro. 24. The method according to p. 17, characterized in that the neoplastic cell is treated in vitro. 25. Способ по п. 17, отличающийся тем, что упомянутая неопластическая клетка является клеткой костного мозга. 25. The method of claim 17, wherein said neoplastic cell is a bone marrow cell. 26. Способ уничтожения неопластических клеток в костном мозгу, предусматривающий стадию удаления костного мозга из индивидуума, имеющего неопластическое заболевание, контактирование костного мозга с эффективной в разрушении клеток дозой композиции по п. 1 и возврат обработанного костного мозга индивидууму. 26. A method of destroying neoplastic cells in the bone marrow, comprising the step of removing bone marrow from an individual having a neoplastic disease, contacting the bone marrow with an effective cell destruction dose of the composition of claim 1, and returning the treated bone marrow to the individual. 27. Способ по п. 26, отличающийся тем, что упомянутые неопластические клетки отличаются избыточной экспрессией белка с-erb В-2. 27. The method according to p. 26, characterized in that the said neoplastic cells are characterized by excessive expression of c-erb B-2 protein.
RU94045908A 1992-04-10 1993-04-08 Composition and method for treating neoplastic cells RU2130780C1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86772892A 1992-04-10 1992-04-10
US07/867.728 1992-04-10
US07/867,728 1992-04-10
PCT/US1993/003292 WO1993021232A1 (en) 1992-04-10 1993-04-08 IMMUNOTOXINS DIRECTED AGAINST c-erbB-2 (HER-2/neu) RELATED SURFACE ANTIGENS

Publications (2)

Publication Number Publication Date
RU94045908A true RU94045908A (en) 1997-11-27
RU2130780C1 RU2130780C1 (en) 1999-05-27

Family

ID=25350363

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045908A RU2130780C1 (en) 1992-04-10 1993-04-08 Composition and method for treating neoplastic cells

Country Status (18)

Country Link
EP (1) EP0635030B1 (en)
JP (1) JP3633613B2 (en)
KR (1) KR100333011B1 (en)
AT (1) ATE271564T1 (en)
AU (1) AU671642B2 (en)
CA (1) CA2133739A1 (en)
DE (1) DE69333574T2 (en)
DK (1) DK0635030T3 (en)
ES (1) ES2224099T3 (en)
FI (1) FI113243B (en)
IL (1) IL105345A (en)
NO (1) NO318173B1 (en)
NZ (1) NZ252800A (en)
PT (1) PT635030E (en)
RU (1) RU2130780C1 (en)
SA (1) SA93140304B1 (en)
WO (1) WO1993021232A1 (en)
ZA (1) ZA932522B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010594B1 (en) * 2001-05-24 2008-10-30 Займодженетикс, Инк. Taci-immunoglobulin fusion proteins

Families Citing this family (474)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc Human endokine alpha and methods of use
EP2112167A3 (en) 1999-06-25 2010-12-22 Genentech, Inc. Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
ATE438411T1 (en) 1999-08-27 2009-08-15 Genentech Inc DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
ATE441433T1 (en) 2000-05-19 2009-09-15 Genentech Inc GENETIC DETECTION METHOD TO IMPROVE THE PROBABILITY OF AN EFFECTIVE RESPONSE TO CANCER THERAPY WITH A HERITAGE ANTAGONIST
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2281843T (en) 2000-06-16 2017-01-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
EP2052742A1 (en) 2000-06-20 2009-04-29 Biogen Idec Inc. Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP2184291A1 (en) 2000-08-18 2010-05-12 Dyax Corp. Binding polypeptides for B lymphocyte stimulator protein (BLyS)
EP2338512A1 (en) 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
KR20030093316A (en) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 Vascular endothelial growth factor 2
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
ES2372321T3 (en) 2001-06-20 2012-01-18 Genentech, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF A LUNG TUMOR.
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
KR101008758B1 (en) 2001-09-18 2011-01-14 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
KR100623128B1 (en) 2002-01-02 2006-09-14 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EA011853B1 (en) 2002-03-13 2009-06-30 Байоджен Айдек Ма Инк. ANTI- αβANTIBODIES
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc Recombinant anti-interleukin-9 antibodies
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2070949B1 (en) 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
MXPA05000403A (en) 2002-07-15 2005-07-22 Genentech Inc METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES.
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
CN101987871A (en) 2002-09-27 2011-03-23 赞科股份有限公司 Optimized fc variants and methods for their generation
EP2891666B1 (en) 2002-10-16 2017-06-28 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2004091657A2 (en) 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
NZ544317A (en) 2003-07-08 2009-05-31 Genentech Inc IL-17 A/F heterologous polypeptides and therapeutic uses thereof
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
ES2472690T3 (en) 2003-11-17 2014-07-02 Genentech, Inc. Antibody against CD22 for the treatment of tumors of hematopoietic origin
PL1718677T3 (en) 2003-12-19 2012-09-28 Genentech Inc Monovalent antibody fragments useful as therapeutics
ES2533084T3 (en) 2003-12-23 2015-04-07 Genentech, Inc. Cancer treatment with novel anti-IL 13 monoclonal antibodies
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP1737489B1 (en) 2004-04-08 2012-01-11 David B Agus ErbB2 antagonists for tumor pain therapy
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
SV2006002143A (en) 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
MXPA06014684A (en) 2004-06-18 2007-02-12 Ambrx Inc Novel antigen-binding polypeptides and their uses.
AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc Optimized Fc variants
ATE456579T1 (en) 2004-07-20 2010-02-15 Genentech Inc ANGIOPOIETIN-LIKE 4 PROTEIN INHIBITOR COMBINATIONS AND THEIR USE
KR20180091967A (en) 2004-07-22 2018-08-16 제넨테크, 인크. Her2 antibody composition
WO2006014928A1 (en) 2004-07-26 2006-02-09 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activation
SI1784426T1 (en) 2004-09-03 2012-03-30 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
PL1791565T3 (en) 2004-09-23 2016-10-31 Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
DE602006013275D1 (en) 2005-01-07 2010-05-12 Diadexus Inc OVR110 ANTIBODY COMPOSITIONS AND USER METHOD THEREFOR
CN101141981A (en) 2005-01-21 2008-03-12 健泰科生物技术公司 Fixed dosing of her antibodies
DK1853718T3 (en) 2005-02-15 2015-11-09 Univ Duke ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
EP2399605A1 (en) 2005-02-23 2011-12-28 Genentech, Inc. Extending time to disease progression or survival in cancer patients
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
CA2604885A1 (en) 2005-04-07 2006-10-19 Guoying Yu Cacna1e in cancer diagnosis, detection and treatment
WO2006121852A2 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
ES2561628T3 (en) 2005-05-06 2016-02-29 Zymogenetics, Inc. IL-31 monoclonal antibodies and methods of use
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
CN102875681A (en) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
JP2009504183A (en) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド Gene disruption and related compositions and methods
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20150055628A (en) 2005-11-04 2015-05-21 제넨테크, 인크. Use of complement pathway inhibitors to treat ocular diseases
EA014900B1 (en) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Compositions and methods for controlling tissue factor signaling specificity
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
CA2631327C (en) 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
WO2007126439A2 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EP1973948B1 (en) 2005-12-15 2015-02-11 Genentech, Inc. Methods and compositions for targeting polyubiquitin
SI1973950T1 (en) 2006-01-05 2015-01-30 Genentech, Inc. Anti-ephb4 antibodies and methods using the same
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2650306A1 (en) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2007103522A2 (en) 2006-03-08 2007-09-13 Wake Forest University Health Sciences Soluble monomeric ephrin a1
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
EP2389951A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2012827A2 (en) 2006-04-13 2009-01-14 Novartis Vaccines and Diagnostics, Inc. Methods of treating, diagnosing or detecting cancer
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
MX2008015132A (en) 2006-05-30 2008-12-10 Genentech Inc Antibodies and immunoconjugates and uses therefor.
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008008315A2 (en) 2006-07-10 2008-01-17 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
ME01786B (en) 2006-08-14 2014-09-20 Xencor Inc Optimized antibodies that target cd19
EP2061900A2 (en) 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
CA2660175C (en) 2006-09-01 2015-05-12 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
ES2636089T3 (en) 2006-10-27 2017-10-05 Genentech, Inc. Antibodies and immunoconjugates and uses for them
CA2670696A1 (en) 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
JP5386364B2 (en) 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド Anti-Notch3 antagonist antibodies and their use in the prevention and treatment of Notch3-related diseases
CA2676766A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
EP2125898B1 (en) 2007-03-14 2013-05-15 Novartis AG Apcdd1 inhibitors for treating, diagnosing or detecting cancer
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
TWI570135B (en) 2007-04-27 2017-02-11 建南德克公司 Potent, stable and non-immunosuppressive anti-cd4 antibodies
SG194368A1 (en) 2007-05-04 2013-11-29 Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa Engineered rabbit antibody variable domains and uses thereof
CN101861168B (en) 2007-05-07 2014-07-02 米迪缪尼有限公司 Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
JP2010533495A (en) 2007-07-16 2010-10-28 ジェネンテック， インコーポレイテッド Humanized CD79b antibodies and immunoconjugates and their use
PT2176296E (en) 2007-07-16 2012-05-14 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
EP2195425A4 (en) 2007-08-24 2011-01-19 Oncotherapy Science Inc Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis
UA117446C2 (en) 2007-08-29 2018-08-10 Санофі-Авентіс HUMANIZED ANTIBODY TO CXCR5
CA2698809C (en) 2007-09-14 2023-10-17 Amgen Inc. Homogeneous antibody populations
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009064805A1 (en) 2007-11-12 2009-05-22 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of influenza
AR069501A1 (en) 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
EP3825329A1 (en) 2007-12-26 2021-05-26 Xencor, Inc. Fc variants with altered binding to fcrn
US8637026B2 (en) 2007-12-26 2014-01-28 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
JP2011509650A (en) 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス Humanized anti-α9 integrin antibody and use thereof
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MY157403A (en) 2008-01-31 2016-06-15 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
PT2250279E (en) 2008-02-08 2016-06-03 Medimmune Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
WO2009114560A2 (en) 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus
US20090258013A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2009131256A1 (en) 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
CA2726131C (en) 2008-05-29 2018-03-13 Baoming Jiang Expression and assembly of human group c rotavirus-like particles and uses thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
KR20110025215A (en) 2008-06-30 2011-03-09 온코세라피 사이언스 가부시키가이샤 Anti-cdh3antibodies labeled with radioisotope label and uses thereof
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CN102317315A (en) 2009-02-11 2012-01-11 诺维信生物制药丹麦公司 Albumin variants and conjugates
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
AU2010221993C1 (en) 2009-03-10 2015-07-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized K33N monoclonal antibody
SI3260136T1 (en) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv) -neutralizing antibodies
KR20130080871A (en) 2009-03-20 2013-07-15 제넨테크, 인크. Bispecific anti-her antibodies
CN104788564A (en) 2009-03-25 2015-07-22 健泰科生物技术公司 Anti-FGFR3 antibodies and methods using same
JP6132548B2 (en) 2009-04-01 2017-05-24 ジェネンテック， インコーポレイテッド Anti-FcRH5 antibodies and immunoconjugates and methods of use
JP5501439B2 (en) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト Multispecific antibody comprising a full-length antibody and a single chain Fab fragment
WO2010121125A1 (en) 2009-04-17 2010-10-21 Wake Forest University Health Sciences Il-13 receptor binding peptides
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN102421448A (en) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Modulators for her2 signaling in her2 expressing patients with gastric cancer
PL2896404T3 (en) 2009-06-04 2017-12-29 Novartis Ag Methods for identification of sites for IgG conjugation
EP2445520A4 (en) 2009-06-22 2013-03-06 Medimmune Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP2459591B1 (en) 2009-07-31 2014-08-20 Genentech, Inc. Inhibition of tumor metastasis using anti-g-csf-antibodies
JP5887270B2 (en) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド Mutant SMOOTHENED AND METHOD OF USING THE SAME
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011045396A2 (en) 2009-10-16 2011-04-21 Novartis Ag Biomarkers of tumor pharmacodynamic response
CN102791739B (en) 2009-10-19 2014-10-15 霍夫曼-拉罗奇有限公司 Modulators of hepatocyte growth factor activator
ES2564207T3 (en) 2009-10-22 2016-03-18 F. Hoffmann-La Roche Ag Methods and compositions for modulating hepsin activation of macrophage stimulating protein
AR078716A1 (en) 2009-10-22 2011-11-30 Genentech Inc ANTIHEPSIN ANTIBODIES AND METHODS FOR USE
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
JP2013509170A (en) 2009-10-30 2013-03-14 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ Albumin variant
SI2496601T1 (en) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Methods and composition for secretion of heterologous polypeptides
EP3002297B1 (en) 2009-11-30 2020-04-08 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
AR078377A1 (en) 2009-12-11 2011-11-02 Genentech Inc ANTI-VEGF-C ANTIBODIES (ISOLATED ANTI-VASCULAR ENDOTELIAL GROWTH FACTOR C) AND ITS METHODS OF USE
KR101961495B1 (en) 2009-12-23 2019-03-22 아비펩 피티와이 리미티트 Immuno-conjugates and methods for producing them 2
HUE028629T2 (en) 2009-12-23 2016-12-28 Synimmune Gmbh Anti-flt3 antibodies and methods of using the same
EP2516465B1 (en) 2009-12-23 2016-05-18 F.Hoffmann-La Roche Ag Anti-bv8 antibodies and uses thereof
EP2519542B1 (en) 2009-12-28 2018-10-10 OncoTherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
MX341687B (en) 2010-02-10 2016-08-30 Immunogen Inc Cd20 antibodies and uses thereof.
SI2536748T1 (en) 2010-02-18 2014-12-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
KR20130004579A (en) 2010-02-23 2013-01-11 제넨테크, 인크. Compositions and methods for the diagnosis and treatment of tumor
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
MX341925B (en) 2010-03-29 2016-09-07 Zymeworks Inc Antibodies with enhanced or suppressed effector function.
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
RU2624027C2 (en) 2010-04-23 2017-06-30 Дженентек, Инк. Heteromultimeric proteins production
RU2636461C2 (en) 2010-05-03 2017-11-23 Дженентек, Инк. Compositions and methods for diagnosis and treatment of tumour
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
MX336540B (en) 2010-06-08 2016-01-22 Genentech Inc Cysteine engineered antibodies and conjugates.
EP4269563A3 (en) 2010-06-19 2024-01-10 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
US8900590B2 (en) 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
SG187965A1 (en) 2010-08-27 2013-04-30 Stem Centrx Inc Notum protein modulators and methods of use
CA3109036C (en) 2010-08-31 2023-08-01 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
NZ607510A (en) 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
PL2621526T3 (en) 2010-09-29 2018-11-30 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
BR112013011811A2 (en) 2010-11-05 2023-02-23 Zymeworks Inc STABLE HETERODIMERIC ANTIBODY MODEL WITH MUTATIONS IN THE FC DOMAIN
JP6296536B2 (en) 2010-11-05 2018-03-20 メドベット サイエンス ピーティーワイエルティーディーＭｅｄｖｅｔ Ｓｃｉｅｎｃｅ Ｐｔｙ Ｌｔｄ Endothelial progenitor cell markers and uses thereof
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
RU2016123839A (en) 2010-12-08 2018-11-30 АббВай Стемсентркс ЭлЭлСи New modulators and methods of their application
EP2654790B1 (en) 2010-12-22 2019-02-06 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
MX355255B (en) 2011-02-04 2018-04-11 Genentech Inc Fc VARIANTS AND METHODS FOR THEIR PRODUCTION.
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
KR20140012098A (en) 2011-02-14 2014-01-29 테라클론 사이언시스, 아이엔씨. Compositions and methods for the therapy and diagnosis of influenza
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
WO2012118813A2 (en) 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
SG193402A1 (en) 2011-03-15 2013-10-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
EP2699597B1 (en) 2011-04-21 2016-06-01 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them b
MX339239B (en) 2011-04-29 2016-05-18 Apexigen Inc Anti-cd40 antibodies and methods of use.
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
KR101972446B1 (en) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Bcma(cd269/tnfrsf17)-binding proteins
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
BR112014003431A2 (en) 2011-08-17 2017-06-13 Genentech Inc antibody, nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, pharmaceutical agent, use of the antibody, method of treating an individual who has cancer, and time-lapse method for tumor recurrence
MX2014001736A (en) 2011-08-17 2014-03-31 Genentech Inc Inhibition of angiogenesis in refractory tumors.
JP6244301B2 (en) 2011-08-18 2017-12-06 アフィニティ バイオサイエンス ピーティーワイ リミテッド Soluble polypeptide
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20150044208A1 (en) 2011-09-23 2015-02-12 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
EP2766392B1 (en) 2011-10-10 2019-07-17 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2851667A1 (en) 2011-10-11 2013-04-18 Medimmune, Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
TW201325613A (en) 2011-10-28 2013-07-01 Genentech Inc Therapeutic combinations and methods of treating melanoma
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
CN104053671A (en) 2011-11-01 2014-09-17 生态学有限公司 Antibodies and methods of treating cancer
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067098A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
RS62689B1 (en) 2011-11-04 2021-12-31 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
SG11201402619VA (en) 2011-11-23 2014-10-30 Igenica Biotherapeutics Inc Anti-cd98 antibodies and methods of use thereof
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
JP6684490B2 (en) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining regions and uses thereof
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
MX2014009565A (en) 2012-02-10 2014-11-10 Genentech Inc Single-chain antibodies and other heteromultimers.
LT2814844T (en) 2012-02-15 2017-10-25 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
WO2013120554A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
PE20190658A1 (en) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc NEW MODULATORS AND EMPLOYMENT METHODS
KR20140136934A (en) 2012-03-16 2014-12-01 노보자임스 바이오파마 디케이 에이/에스 Albumin variants
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
BR112014024017A8 (en) 2012-03-27 2017-07-25 Genentech Inc METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CN104470544B (en) 2012-05-01 2018-01-12 基因泰克公司 Anti- PMEL17 antibody and immunoconjugates
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
ES2597228T3 (en) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedure for the selection and production of objectification entities, such as targets, highly selective and multi-specific, customized, which contain at least two different binding entities, and use of these
WO2014006124A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
KR20150030755A (en) 2012-07-04 2015-03-20 에프. 호프만-라 로슈 아게 Anti-biotin antibodies and methods of use
HUE029435T2 (en) 2012-07-04 2017-02-28 Hoffmann La Roche Anti-theophylline antibodies and methods of use
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
TR201900694T4 (en) 2012-08-23 2019-02-21 Agensys Inc Antibody drug conjugates (ADC) that bind to 158p1d7 proteins.
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
CN104918957B (en) 2012-10-30 2018-11-16 埃派斯进有限公司 Anti-CD 40 antibodies and its application method
BR112015010318A2 (en) 2012-11-08 2017-08-22 Albumedix As ALBUMIN VARIANTS
CN104813168B (en) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 Need the identification of the patient of PD L1 inhibitor composite treatments
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2943511B1 (en) 2013-01-14 2019-08-07 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
BR112015022019A2 (en) 2013-03-14 2017-08-29 Genentech Inc ISOLATED ANTIBODIES, NUCLEIC ACID, HOST CELL, METHOD OF PRODUCING ANTIBODIES, IMMUNOCONJUGATE, PHARMACEUTICAL FORMULATION, METHODS FOR TREATMENT OF INDIVIDUALS, INHIBITION OF CELL PROLIFERATION, DETECTION OF HUMAN B7-H4 AND CANCER DETECTION
ES2885696T3 (en) 2013-03-15 2021-12-15 Xencor Inc Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
JP6482525B2 (en) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター High affinity anti-GD2 antibody
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
EP3022221B1 (en) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
TWI646108B (en) 2013-08-01 2019-01-01 艾澤西公司 Antibody drug conjugate (ADC) that binds to CD37 protein
MX2016001854A (en) 2013-08-12 2016-09-06 Genentech Inc Compositions and method for treating complement-associated conditions.
JP2016538318A (en) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド New SEZ6 modulator and method of use
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
AR097685A1 (en) 2013-09-17 2016-04-06 Genentech Inc METHODS OF USE OF ANTI-LGR5 ANTIBODIES
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015054427A1 (en) 2013-10-10 2015-04-16 Beth Israel Deaconess Medical Center, Inc. Tm4sf1 binding proteins and methods of using same
US10081682B2 (en) 2013-10-11 2018-09-25 Oxford Bio Therapeutics Ltd. Conjugated antibodies against LY75 for the treatment of cancer
EP3068797B1 (en) 2013-11-11 2020-01-08 Wake Forest University Health Sciences Constructs for multi-valent targeting of tumors
KR20160098328A (en) 2013-12-13 2016-08-18 제넨테크, 인크. Anti-cd33 antibodies and immunoconjugates
CA2933557A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CA2930046A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked polypeptide toxin-antibody conjugates
BR112016013849A2 (en) 2014-01-03 2017-10-10 Hoffmann La Roche bispecific antihapten / blood-brain barrier receptor conjugates, their uses, and pharmaceutical formulation
JP6602304B2 (en) 2014-01-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー Covalently linked helicer-anti-helicer antibody conjugates and uses thereof
KR20160104727A (en) 2014-01-16 2016-09-05 아카데미아 시니카 Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017505305A (en) 2014-01-24 2017-02-16 ジェネンテック， インコーポレイテッド Methods using anti-STEAP1 antibodies and immunoconjugates
JP6736467B2 (en) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド Smoothing mutant and method of using the same
KR20220025946A (en) 2014-03-21 2022-03-03 애브비 인코포레이티드 Anti-egfr antibodies and antibody drug conjugates
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
JP6775422B2 (en) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Bispecific antibody that binds to CD38 and CD3
MX2016012873A (en) 2014-04-04 2017-03-07 Bionomics Inc Humanized antibodies that bind lgr5.
EP3129055B1 (en) 2014-04-11 2020-07-01 MedImmune, LLC Bispecific her2 antibodies
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
EP3888690A3 (en) 2014-05-16 2021-10-20 MedImmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
BR112016027222A2 (en) 2014-05-22 2018-01-30 Genentech Inc isolated antibodies, isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, methods of treating an individual with cancer, inhibiting cell proliferation, detecting human gpc3 and detecting a cancer
KR20170005142A (en) 2014-05-27 2017-01-11 아카데미아 시니카 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149036A4 (en) 2014-05-27 2017-12-27 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7063538B2 (en) 2014-05-28 2022-05-09 アカデミア シニカ Anti-TNFα sugar-manipulated antibody group and its use
MY178347A (en) 2014-07-17 2020-10-08 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CA2959141A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
TWI745275B (en) 2014-09-08 2021-11-11 中央研究院 HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
SI3191135T1 (en) 2014-09-12 2021-01-29 Genentech, Inc. Anti-her2 antibodies and immunoconjugates
CA2958479A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
CN113698488A (en) 2014-09-12 2021-11-26 基因泰克公司 anti-B7-H4 antibodies and immunoconjugates
CA3069221C (en) 2014-09-23 2023-04-04 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CN106922129B (en) 2014-10-01 2024-02-20 免疫医疗有限责任公司 Methods of conjugating polypeptides
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
RU2017119185A (en) 2014-11-05 2018-12-05 Дженентек, Инк. ANTIBODIES AGAINST FGFR2 / 3 AND WAYS OF THEIR APPLICATION
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MA41019A (en) 2014-11-26 2021-05-05 Xencor Inc HETERODIMERIC ANTIBODIES BINDING TO CD3 AND CD38 ANTIGENS
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
PL3227332T3 (en) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2016096741A1 (en) 2014-12-17 2016-06-23 F. Hoffmann-La Roche Ag Novel methods for enzyme mediated polypeptide conjugation using sortase
PL3233910T3 (en) 2014-12-19 2020-06-01 Ablynx N.V. Cysteine linked nanobody dimers
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
EP3242685B1 (en) 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN107614010A (en) 2015-03-09 2018-01-19 艾更斯司股份有限公司 It is bound to the antibody drug conjugates (ADC) of FLT3 albumen
KR20170132793A (en) 2015-04-03 2017-12-04 유레카 쎄라퓨틱스, 인코포레이티드 Constructs targeting AFP peptide / MHC complexes and uses thereof
WO2016172485A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CA2984638A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
RU2020124105A (en) 2015-06-24 2020-09-18 Ф. Хоффманн-Ля Рош Аг ANTIBODIES AGAINST TRANSFERRINE RECEPTOR WITH INDIVIDUAL AFFINITY
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
WO2017050874A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Process for producing thioesters employing a sortase a
BR112018003594A2 (en) 2015-09-25 2018-09-25 Hoffmann La Roche recombinant immunoglobulin heavy chain, antibodies, conjugate production method and conjugates
EP3353314A1 (en) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
EP3353291B1 (en) 2015-09-25 2021-06-09 F. Hoffmann-La Roche AG Novel soluble sortase a
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CR20180149A (en) 2015-10-02 2018-04-05 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST THE HUMAN CD20 AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN108431038A (en) 2015-10-06 2018-08-21 豪夫迈·罗氏有限公司 The method for treating multiple sclerosis
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA43135A (en) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CA3003144A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
JP6991978B2 (en) 2016-01-27 2022-02-03 メディミューン，エルエルシー Methods for Preparing Antibodies with a Defined Glycosylation Pattern
CN109071625A (en) 2016-02-04 2018-12-21 柯瑞斯公司 Smooth mutant and its application method
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
CN108697799A (en) 2016-03-22 2018-10-23 生态学有限公司 The application of anti-LGR5 monoclonal antibodies
JP6727325B2 (en) 2016-03-30 2020-07-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Improved sortase
CA3021086C (en) 2016-04-15 2023-10-17 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
TW202208441A (en) 2016-05-13 2022-03-01 美商拜奧亞特拉公司 Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
BR112018075644A2 (en) 2016-06-08 2019-04-09 Abbvie Inc. anti-cd98 antibodies and antibody and drug conjugates
BR112018075630A2 (en) 2016-06-08 2019-03-19 Abbvie Inc. anti-cd98 antibodies and antibody drug conjugates
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3458479B1 (en) 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US20200338209A1 (en) 2016-06-08 2020-10-29 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
DK3468997T3 (en) 2016-06-08 2023-10-02 Xencor Inc Treatment of IgG4-related diseases with anti-CD9 antibodies cross-linked to CD32B
RU2022104399A (en) 2016-06-14 2022-05-05 Ксенкор, Инк. BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS
CN116063545A (en) 2016-06-28 2023-05-05 Xencor股份有限公司 Heterodimeric antibodies that bind somatostatin receptor 2
JP2019524706A (en) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Use of human epididymis protein 4 (HE4) to assess responsiveness of MUC16 positive cancer treatment
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102649972B1 (en) 2016-10-14 2024-03-22 젠코어 인코포레이티드 IL15/IL15Rα heterodimeric Fc-fusion protein
EP4015532A1 (en) 2016-11-21 2022-06-22 cureab GmbH Anti-gp73 antibodies and immunoconjugates
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TW201831517A (en) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 Constructs targeting histone h3 peptide/mhc complexes and uses thereof
KR102317805B1 (en) 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 Compositions and methods for detecting prostate cancer
SG11201908888VA (en) 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for treating lung cancer
EP3610040A1 (en) 2017-04-12 2020-02-19 H. Hoffnabb-La Roche Ag A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
KR102663596B1 (en) 2017-04-26 2024-05-10 유레카 쎄라퓨틱스, 인코포레이티드 Construct that specifically recognizes glypican 3 and its use
AR111963A1 (en) 2017-05-26 2019-09-04 Univ California METHOD AND MOLECULES
CA3067603A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
EP3697813A1 (en) 2017-10-20 2020-08-26 H. Hoffnabb-La Roche Ag Copy protection for antibodies
JP7438942B2 (en) 2017-10-30 2024-02-27 エフ． ホフマン－ラ ロシュ アーゲー Methods for in vivo generation of multispecific antibodies from monospecific antibodies
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11401345B2 (en) 2017-11-27 2022-08-02 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
PL3720879T3 (en) 2017-12-05 2022-09-12 Progastrine Et Cancers S.À R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
PE20201343A1 (en) 2018-04-02 2020-11-25 Bristol Myers Squibb Co ANTI-TREM-1 ANTIBODIES AND USES OF THEM
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11993661B2 (en) 2018-06-18 2024-05-28 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
WO2020010079A2 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
MX2021010390A (en) 2019-03-01 2021-11-17 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3.
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
KR20220007136A (en) 2019-05-14 2022-01-18 제넨테크, 인크. Methods of Use of Anti-CD79b Immunoconjugates to Treat Follicular Lymphoma
MX2021014932A (en) 2019-06-03 2022-04-06 Univ Chicago Methods and compositions for treating cancer with collagen binding drug carriers.
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
CN114341187A (en) 2019-07-12 2022-04-12 中外制药株式会社 Anti-mutant FGFR3 antibodies and uses thereof
WO2021024133A2 (en) 2019-08-06 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Biopharmacuetical compositions and related methods
KR20220079590A (en) 2019-10-04 2022-06-13 티에이이 라이프 사이언시스 Antibody compositions comprising Fc mutations and site-specific conjugation properties
EP4045090A1 (en) 2019-10-18 2022-08-24 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
JP2023522930A (en) 2020-04-24 2023-06-01 ジェネンテック， インコーポレイテッド Methods of Using Anti-CD79b Immunoconjugates
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
AU2021283933A1 (en) 2020-06-04 2023-01-05 Amgen Inc. Bispecific binding constructs
KR20230023727A (en) 2020-06-11 2023-02-17 제넨테크, 인크. Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods of use thereof
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
CN116783217A (en) 2020-12-03 2023-09-19 安进公司 Immunoglobulin constructs with multiple binding domains
EP4271482A2 (en) 2020-12-31 2023-11-08 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
UY39610A (en) 2021-01-20 2022-08-31 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN117396513A (en) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 Combination therapy for the treatment of cancer
CN117794954A (en) 2021-08-03 2024-03-29 葛兰素史密斯克莱知识产权发展有限公司 Biopharmaceutical composition and method for labeling peptide profile with stable isotope
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
KR20240046524A (en) 2021-08-07 2024-04-09 제넨테크, 인크. Methods of using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
WO2023057893A1 (en) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024121711A1 (en) 2022-12-05 2024-06-13 Glaxosmithkline Intellectual Property Development Limited Methods of treatment using b-cell maturation antigen antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1993003741A1 (en) * 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010594B1 (en) * 2001-05-24 2008-10-30 Займодженетикс, Инк. Taci-immunoglobulin fusion proteins

Similar Documents

Publication Publication Date Title
RU94045908A (en) COMPOSITION, METHOD FOR PROCESSING A NEOPLASTIC CELL, METHOD FOR DESTROYING A NEOPLASTIC CELL
DE69333574D1 (en) IMMUNO TOXINS RELATED TO C-ERB B-2 (HER-2 / NEW)
DE3687779D1 (en) TRICHOTECENE CONJUGATES.
RU2004107695A (en) METHODS FOR REMOVING AMYLOID USING ANTI-AMYLOID ANTIBODIES
DE69129989T2 (en) MEDICINAL COMPOSITION FOR TREATING OR PREVENTING MALIGNER TUMORS
MX9804358A (en) Apoptosis induced by monoclonal antibody anti-her2
FI885543A0 (en) DNA SEGMENT, POLYPEPTIDER OTI ANTI-CROPPAR ANSLUTANDE TILL HUMAN VAEVNADSFAKTOR.
EP0226419A3 (en) Anti-human ovarian cancer immunotoxins and methods of use thereof
KR910000183A (en) Recombinant Sporeworm Vaccine
ATE27915T1 (en) COVALENT CONJUGATES LINKING AN ENZYME AND AN ANTIBODY AND DRUG PREPARATIONS CONTAINING THESE CONJUGATES.
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
ATE101648T1 (en) EXPRESSION OF A TUMOR-SPECIFIC ANTIGEN OF A RECOMBINANT VIRUS VECTOR AND ITS APPLICATION FOR THE CARE OR CURATIVE TREATMENT OF THE RELEVANT TUMORS.
RU94045984A (en) COMPOSITION, METHOD FOR TREATING A NEOPLASTIC CELL, METHOD FOR DESTROYING TUMOR CELLS
DE3752129T2 (en) Use of a monoclonal antibody directed against the 17-1A antigen for the manufacture of a medicament for the treatment of a gastrointestinal tumor
DE69133068D1 (en) TUMOR DESTROYING EFFECTS OF ENTEROTOXINS AND RELATED COMPOUNDS
RU92016354A (en) COMPOSITION, METHODS OF TREATMENT, METHOD OF PREVENTION OF RECURRENCE, METHOD OF ENHANCING CYTOTOXIC ACTIVITY OF IMMUNOTOXIN, METHOD OF ENHANCING CYTOTOXIC ACTION OF CONJUGATE
EP0397700A4 (en) Sf-25 colon adenocarcinoma antigen, and antibodies which recognize this antigen
PT97423A (en) METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES CONJUGATES FOR THE TREATMENT OF NEOPLASMS
PT81093B (en) METHOD FOR PREPARING A THERAPEUTIC COMPOSITION FOR TREATMENT OF A TUMOR
ES556684A0 (en) A PROCEDURE FOR TREATING EFFECT CELLS THAT HAVE SURFACE RECEPTORS FOR THE FC REGION OF AN ANTIBODY
KR880002540A (en) Cytotoxic conjugates for cancer treatment
Weber Smooth muscle fibers of Podocoryne carnea (Hydrozoa) demonstrated by a specific monoclonal antibody and their association with neurons showing FMRFamide-like immunoreactivity
KR920702229A (en) Immunotoxin complex
ATE86261T1 (en) TUMOR-ASSOCIATED ANTIGEN.
Yamada et al. Monoclonal Antibody Specific for the Carp Ependymal and Astroglial Cells